# Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Study · id `cardio:ct-nct03772041` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03772041](<https://clinicaltrials.gov/study/NCT03772041>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03772041

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.

## Technical summary

Registry record NCT03772041. Randomized; double masking; primary purpose treatment. Start 2019-01-16 (actual); primary completion 2020-07-21 (actual). Results posted on 2021-08-05.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 294 participants (enrolled count; ClinicalTrials.gov record NCT03772041, source copy `cardio:ctgov-nct03772041-2021-08-05`, retrieved 2026-10-26)
- Started: 2019-01-16 (actual) (ClinicalTrials.gov record NCT03772041, source copy `cardio:ctgov-nct03772041-2021-08-05`, retrieved 2026-10-26)
- Primary completion: 2020-07-21 (actual) (ClinicalTrials.gov record NCT03772041, source copy `cardio:ctgov-nct03772041-2021-08-05`, retrieved 2026-10-26)
- Completion: 2020-07-29 (actual) (ClinicalTrials.gov record NCT03772041, source copy `cardio:ctgov-nct03772041-2021-08-05`, retrieved 2026-10-26)
- Results first posted: 2021-08-05 (ClinicalTrials.gov record NCT03772041, source copy `cardio:ctgov-nct03772041-2021-08-05`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03772041, source copy `cardio:ctgov-nct03772041-2021-08-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03772041-2021-08-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
- Condition: Congestive Heart Failure
- Intervention (Drug): OPC-61815
- Intervention (Drug): Tolvaptan Tab 15 MG
- Lead sponsor: Otsuka Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Otsuka Pharmaceutical Co., Ltd. (`cardio:org-otsuka-pharmaceutical-co-ltd`)

## Provenance

Content hash: dc0139bd17c06b1cee1de4ba8870dd0ca6790ef6269a03a139c2297b800693b4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
